Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.creator | Lau, E.S. (Emily S.) | - |
| dc.creator | Liu, E. (Elizabeth) | - |
| dc.creator | Paniagua, S.M. (Samantha M.) | - |
| dc.creator | Sarma, A.A. (Amy A.) | - |
| dc.creator | Zampierollo, G. (Giovanna) | - |
| dc.creator | Lopez-Salazar, M.B. (María Begoña) | - |
| dc.creator | Diez-Martinez, J. (Javier) | - |
| dc.creator | Wang, T.J. (Thomas J.) | - |
| dc.creator | Ho, J. E. (Jennifer H.) | - |
| dc.date.accessioned | 2021-09-22T11:34:59Z | - |
| dc.date.available | 2021-09-22T11:34:59Z | - |
| dc.date.issued | 2021 | - |
| dc.identifier.citation | Lau, E. S.; Liu, E.; Paniagua, S. M.; et al. "Galectin-3 inhibition with modified citrus pectin in hypertension". JACC: Basic to Translational Science. 6 (1), 2021, 12 - 21 | es |
| dc.identifier.issn | 2452-302X | - |
| dc.identifier.uri | https://hdl.handle.net/10171/62042 | - |
| dc.description.abstract | We investigated the effect of galectin-3 (Gal-3) inhibition with modified citrus pectin on markers of collagen metabolism in a proof-of-concept randomized placebo-controlled trial of participants with elevated Gal-3 levels and hypertension. Although higher Gal-3 levels were associated with female sex, diabetes, and reduced glomerular filtration rate in cross-sectional analyses, treatment with modified citrus pectin did not change collagen markers. The effect of Gal-3 inhibition among individuals with heart failure warrants further investigation. (C) 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. | - |
| dc.description.sponsorship | This work was supported by National Institutes of Health Grant Nos. NIH-5T32HL094301-07 (to Dr. Lau), R01-HL134893 (to Dr. Ho), R01- HL140224 (to Dr. Ho), and K24-HL153669 (to Dr. Ho) and a Gilead Sciences Research Scholar Award (to Dr. Ho). Dr. Ho has received research grants from Gilead Sciences and Bayer. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. | - |
| dc.language.iso | en | - |
| dc.rights | info:eu-repo/semantics/openAccess | - |
| dc.subject | Cardiac fibrosis | - |
| dc.subject | Galectin-3 | - |
| dc.subject | Heart failure | - |
| dc.title | Galectin-3 inhibition with modified citrus pectin in hypertension | - |
| dc.type | info:eu-repo/semantics/article | - |
| dc.description.note | This is an open access article under the CC BY-NC-ND license | - |
| dc.identifier.doi | 10.1016/j.jacbts.2020.10.006 | - |
| dadun.citation.endingPage | 21 | - |
| dadun.citation.number | 1 | - |
| dadun.citation.publicationName | JACC: Basic to Translational Science | - |
| dadun.citation.startingPage | 12 | - |
| dadun.citation.volume | 6 | - |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.
